CVS Health upgraded by UBS on strong execution, margin improvement

UBS upgraded CVS Health to 'Buy' with a $79 price target, citing strong operational execution, particularly in managing Medicare Advantage utilization and medical costs, which underpins confidence in its recovery trajectory. The firm projects 14% compound annual EPS growth through 2028, exceeding consensus, and notes an improving balance sheet poised for buybacks. Despite potential headwinds from Star ratings and drug pricing, UBS finds CVS's current valuation at ~9x 2026 EPS attractive given its growth outlook.

Analysis

UBS has upgraded CVS Health Corp. to 'Buy' with a new price objective of $79, citing increased confidence in the company's operational turnaround and earnings growth potential. The upgrade is underpinned by two consecutive quarters of strong execution and tangible progress in the Healthcare Benefits (HCB) segment. Critically, management's accurate forecasting of Medicare Advantage utilization trends has bolstered conviction in their ability to manage medical costs, a key factor as CVS reprices approximately half of its loss-making group Medicare Advantage contracts this year. UBS projects a 14% compound annual EPS growth rate through 2028, surpassing the 12% consensus estimate, and anticipates a significant $784 million EBIT contribution in 2026 from improved MA margins. Furthermore, the balance sheet is expected to deleverage to a mid-3x ratio by Q4 2026, creating potential for future share buybacks. Despite trading at a discount to its 10-year average P/E ratio (9x projected 2026 EPS vs. 10x average), the company faces risks from upcoming Medicare Star ratings and potential drug pricing regulations, though UBS views these as manageable given a strong current plan rating mix and limited near-term legislative impact.

Key Decisions for Investors

• Investors should view the UBS upgrade as a key inflection point, signaling that operational improvements in the HCB segment and a clear path to margin recovery in Medicare Advantage are becoming evident.
• The current valuation at approximately 9x projected 2026 earnings presents a potential opportunity, as it is a discount to the historical 10x average despite an above-consensus EPS growth forecast of 14% annually through 2028.
• Monitor the repricing of multi-year group Medicare Advantage contracts and the October Star ratings as near-term catalysts that could validate the bullish thesis and drive performance towards the $79 price target.
• Consider the deleveraging of the balance sheet to a mid-3x ratio by 2026 as a potential catalyst for capital returns, as this could unlock capacity for value-accretive share buybacks.